Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Lancet Infect Dis. 2021 Nov 18;22(3):377–389. doi: 10.1016/S1473-3099(21)00332-7

Figure 1. Trial profile.

Figure 1.

Study completion was defined as staying in the study until the end of malaria transmission follow-up (study day 85 for 4·5×105 (n=5) or 9×105 (n=5) PfSPZ Vaccine; study day 30 for CHMI controls; study day 357 for Pilot 1·8×106 PfSPZ Vaccine; study day 281 for main 1·8×106 PfSPZ Vaccine and placebo). (A) One normal saline subject did not receive ASAQ dose between vaccine dose #2 and #3 given they were recently treated for malaria with artemether-lumefantrine. PfSPZ=Plasmodium falciparum sporozoite